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 Genomic DNA gel electrophoresis 
 
Image.1: Genomic DNA Agarose gel electrophoresis 
 
Image shows 0.8% agarose gel electrophoresis of the genomic DNA. 
Lanes shows the extracted DNA under UV trans illumination on 
ethidium bromide staining 
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ABSTRACT 
 
Introduction 
 
Asthma is a chronic inflammatory disease characterized by hyper-reactive 
airways causing recurrent episodes of wheezing, breathlessness and coughing, 
particularly at night or early in the morning. It has a familial preponderance with a 
polygenic inheritance. Various genetic alterations, single nucleotide polymorphisms 
(SNPs), are known to affect the effective management of asthma. One such 
polymorphism that has not been effectively explored is the G protein coupled receptor 
kinase5 (GRK5).This study aims to explore the effect of GRK5 polymorphism on the 
control and management of bronchial asthma in patients who are receiving inhaled 
corticosteroids. 
Objectives & Methodology 
Our objectives were to study the influence of GRK5 polymorphism on the dose 
and duration of treatment with inhaled glucocorticoids in asthmatics, and to analyze 
the effect of GRK5 polymorphism on disease control. After IHEC approval, we 
obtained written informed consent from asthmatics receiving inhaled steroids, 
collected 2 ml of blood and did a genetic analysis for GRK5 polymorphism on the 
sample. We also collected details of drugs received, dose and duration of therapy. 
Patients were classified as those requiring high dose or low dose inhaled steroid based 
on the GINA Guidelines for Inhaled steroids Dose Equivalence Table. The duration of 
treatment was classified into long term (>3 months) or short term (<3 months). We 
analysed the results from collected data. 
Results & Discussion 
Patients with GRK5 polymorphism required high dose inhaled steroids. This 
association was significant (p<0.005) with an odds ratio of 26.133. However, the 
polymorphism did not have any significant effect on the duration of treatment. 
Surprisingly, patients with GRK5 polymorphism had good disease control (p=0.004) 
with an odds ratio of 6.283. This is in contrast to the expectation that patients with the 
SNP would have poor disease control due to endogenous beta blockade. This finding 
can be explained by the fact that most patients with GRK5 polymorphism required 
high dose inhaled steroid, which may have attenuated disease severity. We also 
analysed all the co-factors which could influence disease control, dose and duration of 
steroid use, using multivariate regression model which confirmed the above results. 
Conclusion: 
Asthmatics with GRK5 polymorphism have a higher probability of requiring 
high dose steroids for adequate control of disease. GRK5 polymorphism does not have 
a significant effect on the duration of drug therapy. Though patients with 
polymorphism are expected to have poor control of their asthma, intake of high dose 
steroids may reverse the effect of the polymorphism and these patients may actually 
have adequate control of their disease. This study is the first of its type done in India - 
analysing the effect of GRK5 polymorphism on steroid therapy in asthmatics. 
 
 
Keywords: Bronchial asthma, GRK5 Polymorphism,Dose,Duration,Control,Inhaled 
steroids 
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INTRODUCTION 
World Health Organisation defines asthma as a disease characterized by 
recurrent attacks of breathlessness and wheezing, which vary in severity and 
frequency from person to person. In an individual, they may occur from hour to 
hour and day to day. 
This condition is due to inflammation of the air passages in the lungs 
and affects the sensitivity of the nerve endings in the airways so they become 
easily irritated. In an attack, the lining of the passages swell causing the 
airways to narrow and reducing the flow of air in and out of the lungs.”1. 
Three hundred million people are reported to be affected by asthma 
worldwide with the global prevalence increasing by 50 per cent every decade2, 
with reports of a higher disease burden in developing countries. Based on a 
survey conducted in four cities in India in 2006, the prevalence of asthma is 
around 2.3 per cent,3whereas in youngsters aged 4-15 years in Chandigarh, 7 
percent prevalence was observed10. A more recent report in 2012, estimated the 
national burden of asthma at 17.23 million.4India accounts for a 33 percent of 
the world’s asthma patients9 
Asthma affects about 300 million people worldwide and causes 250 000 
deaths annually.5It is estimated that an extra 100 million persons will be 
affected with asthma by 20252. The recorded increase in asthma prevalence 
over the last two and half decades is probably the result of differences in 
environment & life style, as modifications in the genetic makeup would take 
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many generations to occur6. Worldwide, the number of cases is doubling every 
ten years &the WHO expects asthma, beside COPD, to become the 
3rdmaincause of mortality by 2020.  
A multicentric epidemiological study on the prevalence of asthma 
among Indian adults using a uniform, valid and standardized methodology 
showed that higher age groups, females, family history of respiratory diseases, 
known history of atopy or allergy, lower socio-economic status and 
urbanization were related to asthma7. In another study in Delhi, parental 
smoking, NSAID usage, exposure to pets, pollution due to traffic congestion 
were shown to be associated with wheezing8. 
Multiple studies have been carried out to investigate the causes and risk 
factors for developing asthma. It has been studied and confirmed that various 
genes and factors in the environment increase the susceptibility to disease11. 
There is evidence of familial aggregation of asthma and atopy, and having a 
family history of asthma is considered to be one of the most important risk 
factors for developing the disease12 
Globally, the cost related to respiratory problems exceeds that of TB and 
HIV/AIDS combined13. Developed countries expect to spend 1-2% of their 
health budget on Asthma2.Thus the burden of the disease is not just the 
associated morbidity and mortality, but also the weakened economic status of 
the patient. Thus there is a need for aggressive management.   
Despite the presence of highly effective curative treatment modalities for 
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the treatment of asthma, the disease is often inadequately controlled in many 
patients. 
Several reasons are quoted for this poor management: patient non-
compliance to treatment and follow up, poor inhalation technique14, presence of 
co-morbid diseases15, triggers like gastro-esophageal reflux disease,16 
respiratory infections17, indoor allergens18, risky environmental exposures19and 
lack of response to medications20.  
Most asthmatics are on chronic treatment with inhaled corticosteroids 
and their disease control depends on their adherence to treatment.Many genetic 
factors can also influence the prevalence and control of asthma, in addition to 
the environmental and biological factors. Various genetic alterations, single 
nucleotide polymorphisms (SNPs) are known to affect the effective 
management of asthma: ADRB2 gene, IL 17, TNF alpha, ADAM 33, DPP10, 
GRPA, etc21. 
One such polymorphism that has not been sufficiently explored is the G 
protein coupled receptor kinase5 (GRK5).This study aims to explore the effect 
of GRK5 polymorphism on the control and management of bronchial asthma in 
patients who are receiving inhaled corticosteroids. 
 
 
 
  
 
 
 
 
 
Aims & Objectives 
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OBJECTIVES: 
Primary Objective: 
1. To study the effect of GRK5 polymorphism on the usage of 
glucocorticoids in patients of bronchial asthma 
 
Secondary Objectives 
1. To study the influence of polymorphism on dosage and duration of 
treatment with inhaled glucocorticoids. 
2. To analyze the effect of GRK5 polymorphism on disease control of 
asthma in patients on glucocorticoids. 
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REVIEW OF LITERATURE 
DEFINITION OF ASTHMA 
The word “asthma” is a Greek word which means “panting” or “gasping 
for breath.” Asthma has been known to mankind since ancient times. 
 The concepts of this disease have changed from one hypothesis to 
another. In the 19th century, Henry Hyde Salter22proposed that both neural and 
vascular mechanisms were involved in disease development. He stated that 
“The inflammation or congestion of mucous surface appears to be the stimulus 
that, through the nerves of the air tubes, excites the muscular wall to contract”. 
Many authors of that time agree that there was a strong neurotic element in 
cases of asthma. Thus, asthma was largely considered to be a psychoneurosis. 
However research done in the late 19th century tilted the etiology 
towards various environmental factors. Pollen was demonstrated to be the 
cause of hay asthma by Charles Blackle23.Similarly, the confirmation of 
smooth muscle antigenic sensitizations in animal models of disease24 and the 
discovery of sensitizing proteins25 further strengthened the role of 
environmental factors in chronic asthmatics. Rackemann26 further 
differentiated asthma as intrinsic and extrinsic based on environmental triggers. 
The CIBA foundation guest symposium27 held in 1958, attempted to 
define asthma: “Asthma refers to a condition in subjects with widespread 
narrowing of bronchial airways which changes in severity over short periods 
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of time either spontaneously or under treatment and is not due to 
cardiovascular disease”27.  
 In 1990, in view of the high causalities’ due to asthma in England, the 
British Thoracic Society released guidelines for the management of asthma28. 
As per these guidelines, “Asthma is a common and chronic inflammatory 
condition of the airways whose cause is not completely understood. As a result 
of inflammation the airways are hyper-responsive and they narrow easily in 
response to a wide range of stimuli. This may result in symptoms like coughing, 
wheezing, chest tightness and dyspnea; these symptoms are often worse at 
night. Narrowing of the airway is usually reversible, but in some patients with 
chronic asthma, the inflammation may lead to irreversible obstruction of 
airflow resulting in poor control”28. 
However it took nearly a century to reach a consensus. In 1991, the 
National Heart Lung & Blood Institute (NHLBI) formulated an expert panel 
group29which put forth a guide for the definition and management of asthma: 
“Asthma is a chronic inflammatory disorder of the airways in which many cells 
and cellular elements play a role: In particular, mast cells, eosinophils, T 
lymphocytes, macrophages, neutrophils and epithelial cells. In susceptible 
individuals, this inflammation causes recurrent episodes of wheeze, 
breathlessness, chest tightness and coughing, particularly at night or in the 
early morning. These episodes are usually associated with widespread but 
variable airflow obstruction that is often reversible either spontaneously or 
with treatment .The inflammation also causes an associated increase in the 
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existing bronchial hyper-responsiveness to a variety of stimuli. Reversibility of 
airflow limitation may be incomplete in some patients with asthma.”29, 30 
 Finally as per the current Global Initiative for Asthma (GINA) 
guidelines31 “Asthma is a chronic inflammatory disorder of the airways in 
which many cellular events play a role. This chronic inflammation is 
associated with airway hyper-responsiveness that leads to recurrent episodes 
of wheezing, breathlessness chest tightness and coughing, particularly at night 
or early in the morning. These episodes are usually associated with airflow 
obstruction within the lung that is often reversible either spontaneously or with 
treatment.” 
 
PATHOPHYSIOLOGY 
 Asthma is associated with chronic inflammation of the mucous 
membrane of the lower respiratory tract. Thus reduction of inflammation is one 
of the main targets of management. 
PATHOLOGY 
 The airway mucous membrane is infiltrated with mast cells, active 
eosinophils and T lymphocytes. This inflammation is usually reduced by 
treatment with corticosteroids. Un-treated and under-treated disease results in 
remodeling of the airways. Basement membrane thickening as a result of 
collagen deposition in the sub epithelial region is observed. The epithelial 
tissue is often weak and has decreased fixation to the bronchial wall, with a 
higher number of epithelial cells within the airway duct. Other features include 
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edematous and thick airways accompanied by obstruction of bronchi due to 
formation of plugs by mucous. Vasodilatation and angiogenesis also occur. 
When viewed with a bronchoscope, the large airways may be narrow, 
erythematous and edematous. Peripheral inflamed airways are found mainly in 
severe asthma with uneven narrowing of airways. 
• Airway Inflammation  
 Inflammation is seen from the trachea to the terminal bronchioles. There 
is good evidence of association between the pattern of inflammation and hyper 
responsiveness with variable airflow obstruction32.The inflammation in 
intrinsic asthma is unique that it is dependent on local IgE production. Acute 
inflammatory episodes are superimposed on this chronic inflammatory state 
which causes acute exacerbations. Although eosinophil infiltration is common, 
some patients with severe asthma have a neutrophilic pattern of inflammation 
that is less sensitive to corticosteroids. 
• Mast cells  
 They initiate response to allergens & other stimuli, like exercise and 
hyperventilation. Activated cells are found at the bronchial epithelium& also in 
the airway smooth-muscle layer but are normally absent in eosinophilic 
bronchitis. Allergens stimulate mast cells through IgE33. They also release 
several mediators of bronchoconstriction. 
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Image1: Pathophysiology of Asthma 
 
• Macrophages and dendritic cells   
Macrophages move within the lumen in asthmatics and get activated by 
allergens. Dendritic cells in the airway epithelium take up allergens and planthe 
assembly of T cells specific to allergens 34.  
• Eosinophils 
 Eosinophil infiltration is a typical facet of asthma and is linked tothe 
development of airway hyper-responsiveness (AHR). They are important in 
airway remodeling and in exacerbations. Reduction of the activity of IL-5 
causes reduction in the circulating eosinophils35. 
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• Neutrophils 
 Severe asthmatics have more activated neutrophils in phlegm and the 
airway. Few patients with mild or moderate disease also have higher numbers 
of airway neutrophils36.  
• Structural cells 
 Structural cells are main sources of release of provocative 
intermediaries. Epithelial cells have important roles in transporting inhaled 
stimulants into an airway and are most likely important target cells meant for 
inhaled corticosteroids (ICS) 39. 
• T lymphocytes  
 They have a significant role in coordinating the inflammatory response 
in asthma by releasing various cytokines. In asthmatics, TH2 cells predominate 
in the airways, while there are more TH1 cells in normal persons. TH2 cells 
cause eosinophilic inflammation and also increase IgE formation37.  
• Inflammatory Mediators 
 Multiple inflammatory mediators are involved in asthma and have 
different effects on airways causing various pathophysiologic changes.40 
a) Cytokines  
Role of cytokines in asthma: 
 TH2 cells, cytokines IL-4, IL-5, and IL-1 →allergic inflammation 
 TNF-α,IL-1β → amplify the inflammatory response 
 Thymic stromal lymphopoietin(TSLP) →release of chemokines that 
selectively attract TH2 cells 
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 IL-10,IL-12 are anti-inflammatory and may be deficient in asthma 41 
 
Image 2: Effect of T Lymphocytes on asthma during inflammation38 
 
 
b) Chemokines 
They act by drawing inflammatory mediators towards the airways from the 
circulation42, 43.  
 CCL17 (TARC) & CCL22 (MDC) 
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Image 3: Inflammatory mediators in asthma146 
 
• Oxidative Stress  
 Activated inflammatory cells produce reactive oxygen species (ROS). 
Augmented oxidative stress is indicated by increased concentration of 8-
isoprostane and ethane in these patients44. Increased oxidative stress reduces 
the response to corticosteroids45. 
• Nitric oxide  
 Nitric oxide (NO) is formed in the airway epithelial cells and 
macrophages46. Higher level of NO is exhaled in asthmatics and may be the 
cause of bronchial vasodilatation in asthma. 
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EFFECTS OF CHRONIC INFLAMMATION ON THE AIRWAYS 
o Airway epithelium 
 Bronchial epithelial shedding is causative of AHR in many ways: 
decrease in barrier function, loss of enzymes that degrade certain peptide 
inflammatory mediators,48loss of endothelium derived relaxing factor (EDRF) 
and reflex neural effects on the airway. 
o Fibrosis 
 There will be sub-epithelial fibrosis with eosinophilic infiltration 
through release of TGF-β.This causes narrowing of the airways leading to poor 
control49, 50. 
o Airway smooth muscle  
 Inflammatory mediator’s alter ionic channels that control the resting 
membrane potential of airway smooth-muscle cells, hence altering their 
excitability. The hypertrophy and hyperplasia51 seen in airway smooth muscle 
in asthmatic bronchi is due to factors like platelet-derived growth factor 
(PDGF) or EDRF. 
o Vascular responses 
 A rise in bronchial mucosal blood flow contributes to airway narrowing. 
There is angiogenesis in asthmatic airways in response to growth factors 
particularly vascular endothelial growth factor (VEGF)52.Microvascular 
leakage from post capillary venules causes edema and plasma exudation. 
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o Mucus hyper-secretion 
 Augmented mucus exudation causes sticky plugs that obstruct diseased 
airways. There will be gland hyperplasia in the sub-mucosal region of larger 
airways& increase in epithelial goblet cells53. 
o Neural regulation  
 Abnormalities in the autonomic pathway add to AHR through discharge 
of acetylcholine (Ach)which acts on muscarinic receptors, causing bronchial 
constriction. Mediators cause reflex cholinergic bronchoconstriction and 
release of neuropeptides54.  
o Airway Remodeling  
As per studies there will be a decline in lung function due to airway 
remodeling; if treated properly patients can maintain normal or near normal 
lung function. Only severe asthmatics show decline in function even after 
treatment55. 
o Airway Hyper-responsiveness 
 AHR is the distinctive feature of asthma which is nothing but excessive 
bronchoconstrictor response to multiple triggers. Rise in AHR is proportional 
to the occurrence of symptoms, and the main focus of treatment is to minimize 
AHR.56 
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RISK FACTORS: 
 Many environmental and genetic risk factors can provoke asthmatic 
symptoms. 
1) Atopy 
 Atopics have a high probability of becoming asthmatics. Asthmatics 
often suffer from allergic rhinitis, which suggests that both genetic and 
environmental factors influence development of disease in atopic individuals57.  
2) Genetic Predisposition 
 The familial association of asthma points to a genetic predisposition of 
asthma. There are many new studies which indicate that the severity depends 
on genotype. Molecular screening with linkage analysis and SNP’s of various 
genes indicates that asthma has a polygenic inheritance58.Newer genes have 
been related to asthma, like ADAM-33,GRK5 and DPP-10, but their effect in 
disease pathogenesis is not yet clear59. Genetic polymorphisms may also be 
significant in shaping the reaction to disease management. 
GPCR & GRK 5  
G protein coupled receptors (GPCRs) sense a wide range of extracellular 
signals, like 
• Hormones 
• Chemokines 
• Light  
• Odorants and Neurotransmitters  
16 
 
Over 1000 types of this receptor are present. All GPCRs known so far mediate 
signals from extracellular to intracellular by stimulating G proteins60. 
GPCRs span around the plasma membrane in a bundle of 7 α helices61.  
Humans express over 800 GPCRs which forms the 3rd biggest group of genes, 
with half of these GPCRs governing sensory perception (smell, taste, and 
vision). The remaining receptors regulate many physiological functions 
including nerve activity, tension of smooth muscle, metabolism, rate and force 
of cardiac contraction, and the secretion of most glands in the body. Some of 
the ligands for GPCRs are  
• Eicosanoids 
• Peptide hormones 
• Neurotransmitters - Acetyl choline 
• Lipid signaling molecules 
• Opioids 
• Biogenic amines - Nor epinephrine 
• Amino acids – GABA 
 GPCRs are important regulators of nerve activity in the central nervous 
system (CNS) and are the receptors for the neurotransmitters of the peripheral 
autonomic nervous system (ANS). Due to their number, physiological 
importance, GPCRs are targets for many drugs; almost half of non-antibiotic 
drugs act through these receptors. 
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ACTIVATION 
When an agonist binds to a GPCR, there is a conformational change in 
the receptor that is transmitted from the ligand-binding pocket to the second 
and third intracellular loops of the receptor which couple to the G protein 
heterotrimer. This conformational change causes α subunit to exchange its 
bound GDP for GTP. Binding of GTP activates the α subunit and causes it to 
release both the βγ dimer and the receptor, and both the GTP-bound α subunit 
and the βγ heterodimer become active signaling molecules62. The interaction of 
the agonist-bound GPCR with G protein is temporary; following activation of 
one G protein, the receptor is freed to interact with other G proteins. Depending 
on the nature of the α subunit, the active, GTP-bound form binds to and 
regulates effectors such as adenylyl cyclase (via Gsα) or phospholipase C (via 
Gqα).  
The βγ subunit can regulate many effectors including ion channels and 
enzymes such as PI3-K. The G protein is dynamic until GTP bound to alpha 
subunit is hydrolyzed to GDP. The alpha subunit has a slow intrinsic rate of 
GTP hydrolysis that is modified by regulators of G protein signaling (RGSs). 
These proteins greatly accelerate hydrolysis of GTP and are potentially 
attractive drug targets63.  
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Image 4: Activation of GPCR147 
 
DESENSITISATION 
 Receptors in addition to regulation of biochemical process & 
physiological function also subject themselves to many homeostatic and 
regulatory controls. These controls include 
• Covalent modification  
• Regulation of synthesis 
• Association with other regulatory proteins 
• Degradation of receptor and 
• Relocalization within cell. 
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Similar regulation of transducer and effector protein occurs through 
modulatory inputs from other receptors, and there is also self-regulation by 
feedback regulation of their own signaling outputs. 
Desensitization may be due to brief inapproachability of the receptor to 
the agonist. Phosphorylation of GPCR by specific GRKs is the main 
mechanism for rapid desensitization. Phosphorylation of agonist-occupied 
GPCRs facilitates binding of cytosolic proteins like arrestins to the receptor 
and ends in uncoupling of the G protein64. 
Image 5: Desensitization of GPCR148 
 
3) Infections 
 Viral infections like rhinovirus are general causes of asthma 
exacerbations. Children who suffer respiratory syncytial virus (RSV) infection 
may have a higher chance of developing asthma in later age. Atypical bacteria 
like Chlamydophila have also been thought to be related to asthma.65 
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4) Diet  
 Studies have shown that low antioxidants66 or high sodium and omega-6 
PUFA67 are associated with an increased risk of asthma. Vitamin D 
deficiency68 may also be associated with development of asthma. However, 
interventional studies with supplementary diets have not supported these facts. 
5) Air Pollution  
 Air pollutants such as SO2and ozone may trigger asthma symptoms. 
Indoor air pollution may be more problematic than outdoor pollution because 
of nitrogen oxides from stoves and passive smoking69, 70, 71, 72.  
6) Occupational Asthma 
 It affects nearly 10% of young adults74. Occupational triggers include 
exposure to animals in lab workers, fungal amylase in bakers. The diagnosis 
can be confirmed when symptoms improve on weekends75. 
7) Obesity 
 Asthma is highly associated with obesity (BMI>30 kg/m2) and it has 
been shown to be associated with poor disease control. Although mechanical 
factors may contribute to this, it could also be linked to the pro-inflammatory 
adipokines and reduced anti-inflammatory adipokines that are released from fat 
stores76.  
8) Other Factors  
• Lower maternal age77 
• Duration of breast-feeding78 
• Prematurity &low birth weight baby79 
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• Inactivity. 
INTRINSIC ASTHMA  
 This is a non-atopic form of asthma. These patients usually have adult-
onset asthma, sometimes associated with aspirin sensitivity and nasal polyps. 
They usually have more severe, persistent asthma80. 
 
ASTHMA TRIGGERS  
1) Allergens  
 One common allergen to increase symptoms is Dermatophagoides 
species &frequent exposure causes chronic symptoms. Animal allergens like 
hair from cats and other pets also worsen symptoms. Some allergens are 
seasonal like pollen, weed, and spores.  
2) Viral infections  
Rhinovirus, 81Respiratory Syncytial Virus, 82Coronavirus83 is the most 
common triggers of acute severe exacerbations. 
3) Pharmacologic agents 
Beta-adrenergic blockers, ACE inhibitors, Aspirin sensitivity84 
4) Exercise 
 Exercise induced hyperventilation can cause bronchial smooth muscle 
constriction. EIA typically starts at the end of exercise and symptoms reduce in 
a few minutes. It worsens during climate changes. 85 
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5) Physical factors 
 Cold air86 and hyperventilation87 may trigger asthma. Laughter88 is also 
another factor. Weather changes also trigger asthma. 
6) Food and diet  
 Shellfish, nutscan sometimes causewheeze. Some additives can worsen 
the symptoms of asthma. Preservatives like Metabisulfite&tartarazine can 
cause triggering of symptoms89. 
7) Hormones 
 There can be premenstrual worsening of symptoms, possibly due to 
reduction in progesterone.Thyrotoxicosis90or hypothyroidism91can also 
increase symptoms. 
8) Gastro Oesophageal reflux disease 
 GERD is quite frequent in asthmatics, sometimes due to drugs92. Reflux 
of acid itself can cause bronchoconstriction93 
9) Stress 
 Asthma symptoms can worsen during periods of stress94.Psychological 
factors can induce bronchial constriction through cholinergic pathways.  
 
CLINICAL FEATURES & DIAGNOSIS 
 The main symptoms of asthma are wheezing, dyspnoea, and cough, 
which are sometimes worse at night and during the early morning hours. 
Mucus secretion will be increased.95There can also be hyperventilation. 
Prodromal symptoms can also occur. 
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 Typical signs include an inspiratory wheeze & hyperinflation. Children 
sometimes have cough-variant asthma96.  
DIAGNOSIS  
1) Pulmonary Function Tests 
• There will be reduced PEF,FEV1and  FEV1/FVC ratio  
• Diurnal variations can be confirmed by twice daily PEF 
• Reduced peak flow and MEF in flow volume loop97, 98 
• Whole-body plethysmography99 - there will be a rise in resistance of 
airways, TLC and RV will be increased 
2) Hematologic Tests  
 RAST101 is done to measure the level of serum IgE. 
3) Imaging 
• Roentgenogram is mostly normal, but in patients with more severe 
disease, it may show hyperinflated lungs.  
• High-resolution computed tomography (CT)– rarely bronchiectasis; 
thickening of airway walls in severe asthmatics. 102 
4) Skin Tests 
 May show positive results in allergic asthma due to inhalant allergens103 
5) Exhaled Nitric Oxide 
 Fractional exhaled nitric oxide (FENO) is now being used as a non-
invasive test to measure bronchial inflammation. The typically elevated levels 
in asthma are reduced by corticosteroids. 104 
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CURRENT TREATMENT 
 
The goal of asthma therapy should be as follows105 
 
 Recommendations by the National Asthma Education & Prevention 
Program (NAEPP)-3 stresses on regular treatment with anti-inflammatory 
drugs like corticosteroids through inhaled route as the main point of 
management of severe bronchial asthma. 
The management includes chronic controller medication and short term 
reliever medications. Long term medications include corticosteroids, long 
acting bronchodilators (LABAs), anti cholinergics, PDE inhibitors, leukotriene 
modifiers, desensitization with single allergen therapy, omalizumab and 
vaccination. 
Short acting reliever medications include beta agonist, high dose 
corticosteroids and antimicrobials with respiratory support if necessary. 
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Image 6: Stepwise treatment of Asthma 
 
 
CONTROLLER THERAPIES 
 
Steroids are the most active drugs currently in use. These drugs cut back 
acute & chronic inflammation, leading to reduction in the signs of respiratory 
disease, increase in flow of air, attenuation of airway hyper-responsiveness and 
decreased asthma recurrences. Such drugs additionally enhance the effect of 
beta agonists. 
CORTICOSTEROIDS 
 
 Oral corticosteroids were used in management of asthma since the 1950s 
and are the most effective controller therapy for asthma. The introduction of 
ICS helped in decreasing the use of oral steroids106.  
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Mechanism of Action 
 Corticosteroids, after entering target cells, bind to glucocorticoid 
receptors (GR).The steroid-GR complex binds to certain genes in the nucleus, 
which causes transcription. They also react with transcription factors and co 
activators and so influence protein synthesis. The repression of transcription 
factors AP-1 and NF-κBmay be the basis of their anti-inflammatory properties. 
Additional mechanisms may include inhibitory action on mitogen activated 
protein (MAP) kinase pathways by inducing MAP kinase phosphatase (MKP-
1) and inhibition of many genes.107 
Anti-Inflammatory Effects in Asthma 
 Corticosteroids affect gene transcription. They stimulate anti- 
inflammatory and suppress pro-inflammatory genes. They have an additional 
inhibitory effect on active mediators. Damaged epithelium is also healed. 
Cytosolic GR bind with steroids; the receptor-ligand complexes translocate into 
the nucleus and inhibit histone acetyl transferase (HAT) activity in two ways: 
directly and, more importantly, by recruiting histone deacetylase (HDAC2). 
Steroids also inhibit cytokine production (e.g., IL-3, 4, 5, 9, 13, TNF-α & GM-
CSF). They also decrease survival of eosinophils.  
Corticosteroids have little action on the contractility of the airway 
smooth muscle (ASM). Hence decrease in symptoms may be due to action on 
chronic inflammation and AHR. ICS have quick effects, reducing AHR and 
concentration of mediators in sputum within a few hours109. It is to be 
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understood that corticosteroids decrease bronchial inflammation but do not 
cure it. 
 
Image 7: Mechanism of anti-Inflammatory Effect in Asthma108 
 
 
Effect on β2 Adrenergic Responsiveness 
 Corticosteroids increase the responsiveness of β adrenergic receptors 
and the increase the effects of beta agonists on ASM. They prevent and reverse 
β receptor desensitization111,112.They also reduce uncoupling of β2 receptors to 
Gs. In animals, they have been shown to reduce down-regulation of β2 
receptors. Likewise β2 Agonists also enhance the action of GR, by increasing 
nuclear translocation of the ligand-GR receptor complex. This has been 
demonstrated in the sputum of asthmatics after ICS and inhaled LABA113. 
 
28 
 
Image 8: Effect of Corticosteroids on Airways110 
 
 
Pharmacokinetics 
 Drug inhaled into the lungs acts locally on the mucosa. A small portion 
of drug may be absorbed systemically from the pharyngeal and bronchial 
surface. Use of spacer with MDI decreases the systemic absorption of 
ICS.Beclomethasone and ciclesonide are available as pro-drugs that release the 
active component locally. Budesonide and fluticasone have a higher first-pass 
effect than beclomethasone. 
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Routes of Administration &Dosing of Inhaled Corticosteroids in Asthma 
 ICS are the initial therapy for all patients with chronic asthma. They 
may be prescribed for an asthmatic who need twice weekly beta agonists for 
control. They are used in all types of asthma and in all age groups 114,115.  
 When ICS is used twice daily it improves patient compliance. Once 
daily administration is effective only when doses ≤400 µg/day are used. If a 
dose >800 µg is used, a spacer device should be used to reduce side effects. 
The least possible dose must be used to reduce symptoms116. Nebulizer steroids 
are used in small children who can’t use inhalers. 
Systemic Steroids 
 IV steroids are used in acute exacerbations with PFT <30% predicted 
and when asthmatics are not responding to beta agonist. Hydrocortisone is most 
commonly used due to its rapid onset of action. It can be switched to oral 
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prednisolone later. The usual maintenance dose is 10-15 mg/day. Short courses 
are advised for exacerbations; dose should be tapered before stopping. 
Side Effects: 
Local: 
o Dysphonia 
o Oropharyngeal candidiasis 
o Cough 
Systemic: 
o Osteoporosis 
o Cataracts 
o Glaucoma 
o Metabolic abnormalities (glucose, insulin, triglycerides) 
o Psychiatric disturbances (euphoria, depression) 
o Growth suppression 
o Adrenal suppression and insufficiency 
Therapeutic Choices 
 Inhaled steroids now available are 
 Beclomethasone 
 Budesonide 
 Flunisolide 
 Ciclesonide 
 Triamcinolone 
 Fluticasone  
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 MometasoneFuroate 
  All ICS are absorbed from the lung into the systemic circulation. 
Triamcinolone and flunisolideare the least potent, beclomethasone and 
budesonide are of equal potency; fluticasone is twice as potent as 
beclomethasone. 
 Several studies150 have classified patients who receive inhaled 
corticosteroids for a period greater than 3 months as requiring “long term 
therapy” 
 The potency and dosage of individual drugs of inhaled corticosteroids 
are well defined in the GINA guidelines for asthma 2015 and are given in the 
table below .149 
Image 10: Inhaled corticosteroids Dose equivalents 
 
Corticosteroid-Resistant Asthma 
 This happens due to molecular abnormalities causing impaired anti-
inf1ammatory action of corticosteroids. Complete resistance is very rare. 
Several mechanisms that have been described like 
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 Rise in the spliced form of  glucocorticoid receptor  
 Atypical histone acetylation  
 Defective IL- 10 production 
 Reduced HDAC2 activity  
 
BRONCHODILATOR DRUGS: 
 Their focus is mainly on ASM to reduce bronchial constriction giving a 
quick relief from symptoms117. Three classes are there namely 
 ß2-adrenergic agonist – more effective118 
 Anticholinergics119 
 Theophylline120 
 
ß2-Agonists121  
 They activate ß2-adrenergic receptors present in airways; they couple 
with Gs-protein to adenylyl cyclase there by increasing cAMP, which causes 
smooth muscle relaxation and inhibition of mast cells. Commonly used long 
acting ß2agonists include salmeterol and formoterol. They are available as dry 
powder& are administered using delivery devices. These long acting drugs are 
not used as monotherapy, as they lack anti-inflammatory property. The 
effectiveness of LABA and ICS has led to using them in combination 
medication that delivers both agents at the same time. For acute exacerbation, 
short acting drug are the most effective, which includes albuterol, 
levoalbuterol, terbutaline, pirbuterol etc.  
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 These drugs relax the airways by relaxing the smooth muscle and by 
increasing the airflow, thereby relieving the bronchoconstriction and reducing 
the symptoms. Inhaled β-adrenergic drugs are as effective as oral or parenteral 
therapy. Severe exacerbations often need higher doses.  
 
Anticholinergics121 
 Anticholinergics such as ipratropium bromide and tiotropium bromide 
reduce bronchial constriction and mucus secretion. When compared to beta 
agonists, these are less effective, the reason being specific action on 
bronchoconstriction mediated through cholinergic activation unlike β-
adrenergic drugs which are functional antagonists to various bronchoconstrictor 
stimuli. 
 
Theophylline121 
 Theophylline is an oral bronchodilator, now not used frequently due to 
side effects and other drugs with better efficacy. Mechanism of action is mainly 
through PDE inhibition in ASM. It inhibits HDAC2 by switching off active 
inflammatory genes. They are given as once or twice daily orally. 
Aminophylline is rarely used. The most common side effects are nausea, 
vomiting and headache. 
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OTHER CONTROLLER THERAPIES  
Leukotriene inhibitors: 
 Inhibiting the LT pathways may be valuable in the management of 
asthma, which also led to the development of 5′-LOX inhibitors – zileuton, cys-
LT1 receptor, inhibitors like montelukast, zafirlukast. They are used as add-on 
therapy in patients who are not well controlled on ICS122. They do not appear to 
provide any additional benefit in steroid resistant patients 123. 
Anti-lgE antibody 
 Omalizumab neutralizes circulating IgE and inhibits IgE-mediated 
reactions124. It decreases exacerbations and is used in patient not controlled by 
other modes of treatment. Omalizumab is given as a subcutaneous injection 
every 2-4 wks125, 126. 
 
FUTURE THERAPIES  
Anti-interleukin 4 antibody127-130 
• IL-4 binds to receptor α subunit 
 -type I receptors bind only to IL 4  
            -type II receptors  binds to both IL 4 &13 
 Treatment with Dupilumab(Phase II), a human monoclonal antibody  
binds to interleukin-4 receptor α subunit , reduces exacerbation rates 
• Pitrakinra(Phase II) an interleukin-4 variant  
• Pascolizumab development was stopped early because there was no 
evidence of clinical benefit  
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Anti-interleukin-5 antibody131-134 
               - Mepolizumab (Phase III) 
               - Reslizumab (Phase II)             
         -↓ exacerbations and ↓ use of oral corticosteroids,         
         -without improvement in FEV1 
Anti-interleukin-13 antibody135, 136 
 Interleukin 13 like IL15 also induces corticosteroid insensitivity 
 Lebrikizumab (Phase II) an antibody to IL13, 
              -improved FEV1 in moderate to severe asthma 
              -did not affect exacerbations or asthma symptoms  
Anti-CD25 antibody138 
 Daclizumab, a humanised immunoglobulin G1 monoclonal antibody  
 improved FEV1 and asthma control in adults  
Tyrosine kinase inhibitor137 
 Masitinib, inhibitor of tyrosine kinase that inhibits stem cell factor 
receptor (c-kit) and PDGF 
             - ↓ the dose of oral corticosteroids required 
                       - No effect on lung function 
 
ANTIMICROBIALS139, 140 
Various studies have demonstrated that infection with viruses especially 
rhinovirus and bacteriae like mycoplasma or chlamydia may lead to acute 
exacerbation. Hence usage of antibiotics has been suggested during these 
exacerbations. Regular usage of antibiotics in the absence of exacerbation is 
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not recommended, as there are no consistent testimonies which claim to 
improve clinical outcome with antibiotic usage. Antibiotics ought to be started 
once there is a high probability of evidence for respiratory tract infections like 
pneumonia, fever and sinusitis. 
TOOLS USED: ACT: Asthma control test questionnaire: 
There are multiple methods used to know the range of control in 
asthmatics. ACT and ACQ are the commonly used tests. They're symptom 
based evaluation type of questionnaire while others are based on pulmonary 
function test. ACT in specific has been found to be helpful for primary health 
care development in developing countries94. 
Accurate assessment of control is a very important a part of asthma 
management. Inadequate assessment of control could be a major issue for poor 
control of asthma95.Asthmacontrol test (ACT) is a self-administered tool for 
assessing patient’s control. It comprises 5 item questionnaires which deals with 
symptoms and difficulty in daily activities are recalled for 4 wks, need of 
control medication, and self-rating of control101.  
It has been made known to show a relationship with a physician’s ratings 
of control102. An ACT score >19 indicates well-controlled asthma. ACT has 
conjointly been validated to be used by mail103 and by telephone104. 
The ACT is straightforward to use and provides a numeric score which 
will assist in assessing control over time102. Better assessment of control could 
lead to improved status of patient, awareness, understanding control, and to 
improve patient outcomes. 
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JUSTIFICATION FOR THE STUDY 
From the above discussion about GRK5 it is clear that this has an 
important role in asthma. GRK5 enzyme is controlled by a gene – the GRK5 
gene. An SNP in this gene, at position 41,results in the amino acid glutamine 
(Gln) being changed to leucine(Leu).This polymorphism causes augmented 
receptor desensitization and internalization, which causes various effects in 
various organs141. In relation to asthma, this polymorphism causes beta 
adrenoceptor desensitization leading to enhanced beta blockade, which in turn 
decreases the control of asthma142. 
Some studies show that muscarinic receptor super sensitivity can also 
occur due to this GRK5 polymorphism this can also contribute to poor control 
in asthmatics. GRK5 therefore, regulates pulmonary response in a tissue 
specific and receptor specific manner143. 
Inhaled steroids are highly potent inhibitors of the process of 
inflammation and are commonly used in the management of asthma. They also 
inhibit mediators like cytokines, chemokines and adhesion molecules144 .A 
study was done in rats to determine how glucocorticoids regulated GRK5 
expression. This study revealed that the activity of cytosolic GRK and the 
expression of GRK5 was elevated in the lung of IL-1β-treated rats, and that this 
was completely abolished by dexamethasone. Though dexamethasone only 
partially reversed the loss of IL-1β-induced relaxation activity, it caused 
 complete inhibition of IL
expression145. 
From the above studies it
the regulation of GRK5 by reversing 
possibility of variation in response to gl
polymorphism. There are very few studies exploring 
asthma. No studies have been done so far 
polymorphism on the response 
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METHODOLOGY 
STUDY CENTRE: 
This study was done at Department of Pharmacology, PSG Institute of 
Medical Sciences and Research and the Department of Pulmonology and 
Respiratory Medicine, PSG Hospitals, in collaboration with the PSG Centre for 
Molecular Medicine and Therapeutics (CMMT). 
 
STUDY SUBJECTS: 
Inpatients and outpatients of Respiratory Medicine and Pulmonology 
department with clinical diagnosis of asthma from June 2014 to July 2015 
 
STUDY LOCALE: PSG Hospitals -Coimbatore 
STUDY DESIGN: 
The study was a cross sectional study. After obtaining written informed 
consent from the patients fulfilling the inclusion & exclusion criteria, the study 
participants were given the self-administered questionnaire in the colloquial 
language in order to ensure that they understood the questions before giving 
appropriate responses. During the same visit, blood samples were collected 
from all the patients and genetic analysis was done. 
 
SAMPLE SIZE: 
Sample size of 149 patients who were on inhaled steroids for 
treatment of asthma was chosen for the study. 
 Picture: FLOWCHART OF STUDY DESIGN
 
 
 
SELECTION OF PATIENTS FULFILLING CRITERIA
COMPLETE HISTORY ABOUT DRUG/DOSAGE/DURATION OF 
TREATMENT WITH GLUCOCORTICOIDS
GENETIC ANALYSIS OF GRK 5 POLYMORPHISM
ASSOCIATE WITH USAGE OF GLUCOCORTICOIDS
GETTING IHEC APPROVAL
GETTING INFORMED CONSENT
DRAW BLOOD SAMPLE (2 ML)
FINAL RESULTS AND ANALYSIS
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ETHICAL APPROVAL: 
The study protocol was accepted by the Institutional Human Ethics 
Committee (IHEC) preceding the start of the study. The details and the purpose 
of the study protocol were explained to each participant individually and their 
doubts were clarified before obtaining informed consent. The informed consent 
forms were provided to the participants either in English or Tamil depending 
on the participant. The participants, who gave written informed consent, and 
eligible for recruitment according to the inclusion criteria, were enrolled for the 
study. A copy of the consent form is attached in the annexure. 
 
TOOL USED 
 Case report form 
 Asthma control test - a validated self-administered questionnaire was 
used to assess control of asthma  
o Score more than 19 – Well controlled    
o Score less than or equal to 19 – Poorly controlled 
Patients were classified as those requiring high dose or low dose inhaled 
steroid based on GINA guideline for Inhaled steroids Dose equivalent table. 
The duration of treatment was also classified into long term or short 
term. If the patient was on inhaled steroids for more than 3 months, they were 
categorized as long term users of inhaled steroids while those with less than 3 
months of use were grouped as those on short term treatment.  
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INCLUSION CRITERIA 
 
• All patients diagnosed to have asthma according to the accepted 
guidelines and were under treatment with corticosteroids.  
• Ability and willingness to provide written informed consent  
• Age >12 years  
 
EXCLUSION CRITERIA 
• Asthma patient not on inhaled corticosteroids 
 
GENETIC ANALYSIS: 
Steps involved in genotype analysis were; 
 
 DNA extraction  
 
 TETRA - PCR to amplify GRK 5 gene  
 
 2% Agarose gel electrophoresis  
 
 
Blood Collection and Treatment 
For every 1 ml of whole blood sample, add 0.1 ml of anticoagulant 
(0.5M EDTA pH 8.0). 
Storage of Blood 
Whole blood samples treated with EDTA can be used, either fresh or 
frozen. For short term storage (up to 10 days), collect blood in tubes 
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containing EDTA as an anticoagulant, and store tubes at 2-8ºC. It is 
recommended to store blood samples less than 3 days as DNA degradation 
may occur. For long term storage, collect blood in tubes containing a 
standard anticoagulant (preferably EDTA if high molecular weight DNA is 
required) and store at -80ºC. 
 
DNA EXTRACTION 
Procedure for Extraction Genomic DNA from Blood was done using Kit 
(EZ-10 Spin Column Genomic DNA Minipreps Kit, Blood) and the steps 
followed were the following: 
1. Sample Preparation: 
a. Blood Samples (non-nucleated Erythrocytes, for example Human Blood): 
Collect ~100ul of blood into 2.0 ml centrifuge tube. Add PBS solution to 
the tube to a final volume of 200µL. Vortex softly and let tube stand for 1 
minute at room temperature.  
i. If >100ul of blood is used, add 2 volumes of Buffer TBP. Mix 
thoroughly and make tube stand for 1 minute until red cells lyse 
completely. Spin at 4,000 x g (8,000 rpm) for 1 min. Discard the 
supernatant carefully. Wash the precipitate with 500µl TE Buffer 2 
times. Spin at 4,000 x g (8,000 rpm) for 1 min during each wash. The 
final precipitate should appear white. Proceed with step 2. 
ii. Typical Yield is 1-3µg from 100ul blood sample.  
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b. Blood Samples (Nucleus-containing Erythrocytes, for example chicken 
Blood): Collect ~10µl of blood into a 2.0 ml centrifuge tube. Add PBS 
solution to the tube to a final volume of 200ul. Vortex lightly and allow 
tube to stand for 1 minute at room temperature. Proceed to step 2.  
c. Solidified Blood Clot: Weigh 0.1g of blood. Grind to find powder under 
liquid nitrogen. Add 200ul of PBS solution and proceed to step 2.  
 
2. Add 20µl of proteinase K. Mix well. Add 200 µl of Buffer CL. Vortex 
Gently. Incubate at 56ºC for 10min.  
 The solution should appear clear after complete lysis. If solution still 
appears cloudy, extend incubation time until lysis is complete and 
solution is clear.  
 If RNA-free genomic DNA is necessary, add 20 µl RNase A (10 
mg/ml, not provided with kit), and mix by vortexing, and incubate for 5 
min at room temperature before doing with step 3.  
 If final reaction volume is more than 500ul, increase proteinase K 
usage and/or extend incubation time. DNA Kit Handbook 
 
3. Add 200ul of 100% ethanol to the mixture and mix thoroughly.  
 Small cloudy insoluble material may appear after addition of 
ethanol, but this does not affect the performance of the kit. Proceed 
with step 4.  
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4. Transfer the mixture from step 3 (including any precipitates) into an EZ-
10 column that is in a 2.0 ml Collection Tube. Let it stand at Room 
Temperature for 1-2min. Spin at 8,000 x g (10,000 rpm) for two minutes. 
Throw away the flow-through in the collection tube. 
5. Include 500 µl of CW1 Solution, and spin at 8,000 x g (10,000 rpm) for one 
minute. Next, ensure ethanol has been added to the CW1 concentrate prior to 
usage. 
6.Add 500 µl of CW2 Solution, and spin at 8,000 x g (10,000 rpm) for 1 
minute. Next, ensure ethanol has been added to the CW2 concentrate prior to 
usage. 
7. Throw away the flow-through. Spin at 8,000 x g (10,000 rpm) for an 
additional minute to remove any residual amount of CW2 Solution. 
8.Place the column into a clean 1.5 ml Eppendorf tube. Add 30-50 µl CE 
Buffer into the center of membrane within the column. Incubate at RT for 2 
to 3 minutes. Incubating the tube at 37ºC or 50ºC for 2 minutes may 
increase recovery yield.  
9. Spin at 8,000 x g (10,000 rpm) for 1 minute to elute DNA from the column.  
10. For long term storage, keep aliquots of purified genomic DNA at -
20C. 
11. Measure DNA quantity by UV absorption at A260 (1.0 OD unit is 
equivalent of 50 µg).  
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GRK 5 TETRA PRIMER PCR STANDARDISED PROTOCOL 
REQUIREMENTS: 
1. PRIMERS (SIGMA) 
 
2. DNTPs (HIMEDIA) 
 
3. Taq DNA polymerase (colour Taq Genei) (Stock 1 Unit/ µl, Final con 
0.1 unit)  
4. Taq Buffer A (Genei) (Stock 15mM Mgcl2, Final con 
1.5mMMgcl2)  
5. DNA Sample Optimized concentration: 0.03µg/ 20µL 
6. Milliq water  
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PCR REACTION MIX: 
 
 
PCR PROGRAMME: 
1. Initial denaturation      - 94ºC for 5 min 
2. Denaturation 1              - 94ºC for 30 sec 
3. Annealing      1              - 65ºC for 30 sec             15 CYCLES 
4. Extension       1              - 72ºC for 1 min 
5. Denaturation 2              - 94ºC for 30 sec 
6. Annealing      2              - 55ºC for 30 sec             27 CYCLES 
7. Extension       2              - 72ºC for 1 min 
8. Final extension              - 94ºC for 5 min 
9. Then held at 4ºC 
 PCR amplification confirmed on 2% agarose gel  
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AGAROSE GEL ELECTROPHORESIS 
Reagents required: 
1. TAE buffer 50 X stock: 
 24.2gmTris base 
 5.7ml Glacial Acetic acid 
 10ml 0.5M EDTA pH 8.0 
 Dissolve in 100 ml Distilled water 
2. TAE buffer 1X Tank buffer: 
Dilute the 50X TAE buffer to 1X by adding water. For eg (10ml 
50X TAE + 490ml Water) it becomes 1X TAE. Use it for electrophoresis 
tank to run the gel. 
3. DNA loading dye  
 
4. Ethidium bromide. 
 
5. Agarose powder.  
 
Gel preparation: 
• Take fresh 50ml 1X TAE buffer (based on gel template size) in a 
conical flask and add 1g agarose (2% gel), heat the solution well.  
• Before that seal the Gel template with cello tape and keep the well 
template ready.  
• Then, add 0.2µl ETBR solution with heated 50ml solution mix well 
and pour it in sealed gel template and leave it for a while to become a 
gel.  
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Electrophoresis: 
• Load the 1X TAE buffer in tank (~600ml required) and keep the gel 
plate inside the tank.  
• Then take 2µl DNA loading dye and 8µl DNA (isolated) mix well and 
load it in wells carefully.  
• Set the volt at 65V and run it for 30-45 min. Then analyze the DNA 
bands using gel document machine.  
• Quantification of the extracted genomic DNA was done using 
Nanodrop quantification after 2% agarose gel electrophoresis. 
 
GRK 5 RFLP PCR 
REQUIREMENTS: 
1. PRIMERS (SIGMA) 
 
2.DNTPs(HIMEDIA) 
 
S.NO DNTPSSTOCK 1ºSTOCKCON 2º STOCKCON FINAL CON 
1 100 mM each 
DNTPS 
10 mM each 
DNTPS 
2.5 Mm each 
DNTPS 
100µM 
each 
DNTPS 
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3. Taq DNA polymerase (colour Taq Genei) (Stock 1 Unit/ µl, Final con 
0.1 unit) 
 
4. Taq Buffer A (Genei) (Stock 15mM Mgcl2, Final con 
1.5mMMgcl2) 
5. DNA Sample Optimised concentration: 0.03µg/ 20µL 
 
6. Milliq water 
 
RESTRICTION DIGESTION 
Requirements: 
1. BsrI Enzyme 
2. 10 x Buffer R 
3. PCR product 
 
Optimized Concentration: 
 For wild Homozygous - 2GG 
 For Mutant Homozygous - 2 GG 
 For Heterozygous - 3 GG 
REACTION MIX FOR RFLP: 
 
 
• Mix gently & spin down for few seconds. 
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• Incubate at 65⁰C for 15-40 min. 
 
• Restriction digestion product is inactivated at 80⁰C for 20 min before 
gel electrophoresis. 
 
POLYACRYLAMIDE GEL ELECTROPHORESIS 
The DNA Fragments were separated using 15 % 
Polyacrylamide gel electrophoresis. 
 
  Polyacrylamide gel prepared from the following reaction mix 
 
 
• Polyacrylamide gel was run in Amersham electrophoresis 
system at 100V for about 5 hours 
• The gel was then stained with ethydium bromide 
 
• The stained gel was viewed in a Chemiluminescence gel 
documentation system to identify the DNA fragments 
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IDENTIFICATION OF GENOTYPES 
• Restriction was seen when ‘A’ was present ie (Homozygous) Wild type 
thus produced 202 bp + 179 bp 
• Restriction did not occur when ‘T’ was present ie (Homozygous) Mutant 
type thus produced only 381 bp 
• Restriction occurred when ‘A’ & ‘T’ both were present ie 
(Heterozygous)Wild type thus produced 381 bp + 202 bp + 179 bp 
 
Picture: Showing the Base pair size of the GRK 5 gene 
 
 
 
 
 
  
 
 
 
 
 
Results 
 
  Done using IBM
Square Test for analyzing
high dose, duration of
 Multivariate 
influence of covariates
steroid therapy in asthmatic
Table1: Distribution of Male and Female among asthmatics
SEX 
MALE 
FEMALE 
TOTAL 
Figure 1: Distribution of Male and Female among asthmatics
 Among 149 patients 53(35.5%) were male and 96(64.5%) were female 
which showed a female preponderance at a ratio of 1:1.81.
RESULTS 
STATISTICAL ANALYSIS  
-SPSS software version 22.The analysis
 the various factors influencing the
 drug therapy and control of disease 
Regression analysis model was used
 on above mentioned factors in relation
 patients. 
Distribution of Sex 
 PERCENTAGE
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96 
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 Table 2: Distribution of Age among asthmatics
AGE(IN YEARS)
LESS THAN 30
31-40 
41-50 
51-60 
61-70 
71-80 
MORE THAN 81
TOTAL 
Figure 2: Distribution of Age among asthmatics
In our study, age
± 16.04 years. Patients were more commonly 
39(26%) patients. In our study group, p
were almost equal to patient
there was no statistical 
prevalence of asthma.
0
5
10
15
20
25
30
35
40
LESS 
THAN 
30
31
17
Distribution of Age 
 PERCENTAGE
 17 
22 
39 
27 
29 
12 
 3 
149 
 
 
 of patients ranged from 18-87 years with mean of 50.5 
in the age group of 41
atients with age above 40 years (51%) 
s below 40 years (49%). In addition, 
significance (P=0.954) on influence of age 
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11.5% 
14.7% 
26.2% 
18.1% 
19.5% 
8% 
2% 
100% 
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 Table 3: Incidence of asthma between Urban & Rural Population
URBAN Vs RURAL
URBAN 
RURAL 
TOTAL 
Among our study group urban population was found to be more than 
rural patients which may be due to higher exposure to multiple reasons like air 
pollution, urbanization,  etc. which are risk factors for asthma being more 
common in the urban population 
Figure 3: Incidence of asthma between Urban & Rural Population
Table 4: Frequency of duration of disease
DURATION OF DISEASE
11
MORE THAN 15 YEARS
 In our study group most of the patients had asthmatic symptoms less 
than 5 yrs, whereas only few patients had disease more than 15 years
 PERCENTAGE
109 
40 
149 
 
 
 
DURATION OF DISEASE 
 PERCENTAGE
< 5 YEARS 97 65.4% 
6-10 YEARS 36 24% 
-15 YEARS 10 6.6% 
 6 4% 
TOTAL 149 100% 
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 Figure 4: Frequency of duration of disease
INHALED 
BUDESONIDE
BUDESONIDE/FORMOTEROL
FLUTICASONE
FLUTICASONE/SALMETEROL
TOTAL
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Table 5: Type of steroid therapy 
STEROIDS PERCENTAGE
 53 
 64 
 24 
 8 
 149 
 
Figure 5: Type of steroid therapy 
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35.5% 
42.9% 
16.1% 
5.5% 
100% 
 
 CO MORBIDITIES
PRESENT 
ABSENT 
TOTAL 
 In our study group 29 patients had diabetes mellitus and 34 patients had 
Systemic hypertension
DM
SHT
Table 6: Prevalence of DM & SHT 
 
 DIABETES 
MELLITUS 
SYSTEMIC 
HYPERTENSION
29(19.5%) 34(22.8%)
120(80.5%) 115(77.2%)
149(100%) 149(100%)
 
Figure 6: Prevalence of DM & SHT 
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115
 DAILY DOSE REQUIREMENT
HIGH DOSE 
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 We analyzed patients requiring high dose inhaled steroids based on 
dosage guidelines in GINA report 2015 for different 
corticosteroids. Our patients were mostly on Budesonide or Fluticasone. In our 
study group 34 (23%) patient’s required higher dose of inhaled corticosteroids. 
Rest of 115(77%) required low or medium dosed steroids.
DAILY DOSE REQUIREMENT
DOSE REQUIREMENT 
Table 7: Requirement of high dose  
 
 PERCENTAGE
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Table 7: Requirement of high dose  
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23% 
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100% 
inhalational 
 
 Table 8: Duration of therapy with inhaled steroids
DURATION OF TREATMENT
LONG TERM(> 3 MONTHS)
SHORT TERM(< 3 MONTHS)
Figure 8: Duration of therapy with inhaled steroids
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(more than 3 months) and short term (less than 3 months)
studies done in community
long term treatment, 90(60%) of patients were on long term management of 
more than 3 months while 59(40%) patients were on short term less than 3 
months. 
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TOTAL 
 
Among 149 patients in our study 58 were well controlled 
were poorly controlled
based on ACT (Asthma Control Test) Questionnaire score
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Table 9: Control of disease 
 PERCENTAGE
 58 
 91 
149 
 
 
Figure 9: Control of disease 
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whereas 91 
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Table 10: Distribution of ACT score 
 
 PERCENTAGE
4 
28 
59 
58 
149 
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 GRK5 SINGLE NUCLEOTIDE POLYMORPHISM
SNP 
PRESENT HETEROZYGOUS
HOMOZYGOUS
ABSENT 
TOTAL
Among 149 patients in our study group 17(11.5%) had SNP, 14 were
heterozygous and 3 were homozygous while the rest were wild type
132
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Table 11: Prevalence of SNP 
 
TYPE TOTAL 
 14 17 
 3 
WILD 132 
 149 
 
Figure 11: Prevalence of SNP 
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 Table & Figure 12: Influence of SNP on 
SINGLE NUCLEOTIDE POLYMORPHISM (N=17)
FACTORS
DOSE 
DURATION SHORT TERM
CONTROL 
In our study, among 
required high dose which was statistically significant with P value of 
with Odds ratio of 26.13
steroid therapy for long term 
analyzed for association with 
SNP had good control which was significant with P value of 
ratio of 6.283. 
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NO OF 
PATIENTS 
HIGH DOSE 14 
LOW DOSE 3 
LONG TERM 12 
 7 
GOOD 13 
POOR 4 
 
the 17 patients with SNP, 14(82.4%) patients 
.Also we observed that 12(70.58%) patients required 
but was not statistically significant. When we 
control of the disease, 13 (76.5%) patient
0.004
3
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7
13
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TERM
GOOD POOR
SNP(N=17)
63 
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OVERWEIGHT(>25)
NORMAL(<25)
TOTAL 
 
Among 149 patients in our study group 
than 25 kg/m2.While the rest of patients were below 25 kg/m
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Table 13: Prevalence of BMI 
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Figure 13: Prevalence of BMI 
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their BMI more 
 Table 14: Influence of BMI on 
FACTORS
DOSE 
DURATION SHORT TERM
CONTROL 
In our study, among 
required high dose .Also we observed that 26
therapy for long term. When we analyzed 
disease, 21(42%) patient
higher BMI on all these 3 factors of dose, duration and control were not 
statistically significant with P value more than 0.05.
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50 patients who were overweight, 8
(52%) patients required steroid 
for association with the 
s with overweight had good control. Influence of 
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 Table 15.Prevalence of hazardous 
HAZADROUS EXPOSURE
PRESENT 
ABSENT 
TOTAL 
 
 
Among 149 patients in our study group 
at work like biomass, cotton, tobacco industries while the rest of patients did 
not have hazardous exposure at work.
Figure
HAZADROUS EXPOSURE 
 
exposure
 
 PERCENTAGE
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149 
12(8%) had hazardous exposure 
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 Table 16: Influence of hazardous exposure on 
HAZADROUS EXPOSURE AT WORK
FACTORS
DOSE 
DURATION SHORT TERM
CONTROL 
In our study,
exposure, 4(33.33%
7(58.33%) patients required steroid therapy for long term. When we analyzed 
for association with 
exposure had good control
factors were not statistically signific
Figure 16: Influence of hazardous exposure on 
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PATIENTS 
HIGH DOSE 4 
LOW DOSE 8 
LONG TERM 7 
 5 
GOOD 5 
POOR 7 
 
 among the 12 patients who had history of hazardous 
) patients required high dose. Also we observed that 
control of disease, 5(41.67%) patient with 
. Influence of hazardous exposure on all these 3 
ant with P value more than 0.05.
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 SMOKING
SMOKERS 
NON SMOKERS
TOTAL 
In our study a
which 2 had history of passive smoking and rest of patients were 
 
SMOKING 
Table 17.Prevalence of smoking 
 
 PERCENTAGE
13 
 136 
149 
 
mong 149 patients 13(8.7%) had smoking history among 
Figure 17.Prevalence of smoking 
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 Table 18: Influence of 
FACTORS
DOSE 
DURATION SHORT TERM
CONTROL 
 
In our study, 
patients required high dose 
steroid therapy for long term. When we analyzed
control, 3(23%) patient with 
on all these 3 factors was not statistically significant.
Figure 18: Influence of 
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SMOKING 
 
NO OF 
PATIENTS 
HIGH DOSE 4 
LOW DOSE 9 
LONG TERM 9 
 4 
GOOD 3 
POOR 9 
among 13 patients who had history of smoking, 4
.Also we observed that 9(69.3%) patients required 
 for association with
smoking had good control. Influence of smoking 
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 HISTORY OF ALLERGY OR ATOPY
Table 19.Prevalence of history of allergy or atopy
H/O ALLERGY OR ATOPY
PRESENT 
ABSENT 
TOTAL 
In our study a
environmental allergens
Figure 19.Prevalence of history of allergy or atopy
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56 
149 
 
mong 149 patients 93(62.4%) had history to 
 like cold, dust, season, climate and food.
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 Table 20: Influence of 
HISTORY OF ALLERGY OR ATOPY
FACTORS
DOSE 
DURATION SHORT TERM
CONTROL 
 
In our study among 
14(15%) patients required high dose
required steroid therapy for long term. When we analyzed 
control of disease, 41
Influence of history of allergy on duration and control were not statistically 
significant with P value more than 0.05. But there was no positive correlation 
between allergy and dose requirement, a P value of 0.004 with OR of 0.319.
Figure20: Influence of 
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93 patients who had history of allergen or atopy, 
. Also we observed that 56
for association with 
(44%) patients with history of allergy had good control
history of allergy on dose, duration & control
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 Table 21.Prevalence of
FAMILY HISTORY
PRESENT 
ABSENT 
TOTAL 
In our study a
bronchial asthma. 
Table 21.Prevalence of FAMILY HISTORY
FAMILY HISTORY 
 
 family history 
 
 PERCENTAGE
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mong 149 patients 24(16.1%) had family history of 
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 Table22
FACTORS
CONTROL 
According to our study, positive family history affected the control of 
disease more than dose requirement and duration. In our study, among 24 
patients with family history a lower proportion of patients 7(29%) were under 
good control compared to those with poor control [17(71%)]. But the 
difference was not statistically significant.
Table22
132
: Influence of family history on control
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Table 23.Prevalence of Respiratory co
RESPIRATORY CO MORBIDITIES
PRESENT 
ABSENT 
TOTAL 
In our study a
morbidities like respiratory infections, pneumonia, bronchiectasis etc. 
 
Table 23.Prevalence of Respiratory co morbidities
RESPIRATORY CO MORBIDITIES
-MORBIDITIES 
 
-morbidities
 
 PERCENTAGE
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mong 149 patients 21(14%) had associated respiratory co 
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 Table & Figure 24
FACTORS
DOSE 
DURATION SHORT TERM
CONTROL 
 
In our study,
morbidities, 3(15%) patients required high dose
14(66.66%) patients required steroid therapy for long term. When we analyzed 
for association with 
respiratory co morbidities 
requirement was not statistically significant with P value more than 0.05. But 
patients with respiratory co morbidities had statistically significant effect on 
poor control of disease with P value of 0.044 with OR of 3.
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 Table 25.Prevalence of all
H/O ALLERGIC RHINITIS
PRESENT 
ABSENT 
TOTAL 
In our study a
which is one of most common and important disease associated with asthma.
Figure 25:
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ergic rhinitis 
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55 
94 
149 
 
mong 149 patients 55(37%) had history of allergic rhinitis 
 
 Prevalence of allergic rhinitis 
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 Table26: Influence of 
PRESENCE OF ALLERGIC RHINITIS
FACTORS
DOSE 
DURATION SHORT TERM
CONTROL 
In our study among 
14(25.5%) patients required high dose
required steroid therapy for long term. When we analyzed 
control of disease, 25
Influence of allergic rhinitis on all these 3 factors were not statistically 
significant with P value more than 0.05.
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 PREVIOUS HISTORY OF TUBERCULOSIS
Table 27
PREVIOUS H/O OF TB
PRESENT 
ABSENT 
TOTAL 
In our study group a
TB and they have treatment for the same in the past.
Figure 27
 
.Prevalence of previous history of TB
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mong 149 patients 8(5.4%) had previous history of 
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 Table 28: Influence of 
FACTORS
DOSE 
DURATION SHORT TERM
CONTROL 
In our study, among 
patients required high dose 
steroid therapy for long term. When we analyzed
of disease, 2(25%) patient with 
history of TB on all these 3 factors were not statistically significant with P 
value more than 0.05.
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8 patients who had previous history of TB, 4
.Also we observed that 7(87.5%) patients required 
 the association with
TB had good control. Influence of previous 
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ABSENT 
TOTAL 
In our study a
sleep apnea which is an 
asthma. 
OBSTRUCTIVE SLEEP APNEA 
 
Table 29.Prevalence of OSA 
 
EA PERCENTAGE
13 
136 
149 
 
mong 149 patients 13(8.7%) had history of obstructive 
important co morbid factor influencing severity of 
 
Figure 29: Prevalence of OSA 
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 Table 30: Influence of 
FACTORS
DOSE 
DURATION SHORT TERM
CONTROL 
In our study among 
patients required high dose 
steroid therapy for long term. When we analyzed
disease 2(15.5 %) patient with 
these 3 factors were not statistically significant with P value more than 0.05.
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13 patients who had history of OSA, 1
.Also we observed that 7(53.8 %) patients required 
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OSA had good control. Influence of OSA on all 
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are presently on treatment. 
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Table 31: Prevalence of GERD 
 
GERD PERCENTAGE
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mong 149 patients 16(10.7%) had GERD symptoms and 
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 Table 32: Influence of 
GASTRO ESOPHAGEAL REFLUX DISEASE
FACTORS
DOSE 
DURATION SHORT TERM
CONTROL 
In our study, among 
4(25%) patients required high dose. Also we observed that 5
required steroid therapy for long term. When we analyzed
control of disease, 5(
SNP on all these 3 factors were not statistically significant with P value more 
than 0.05. 
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16 patients who had history of hazardous exposure, 
(
 for association with
31.25%) patient with SNP had good control
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In our study a
includes dog, cat, cattle, birds etc.
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Table 33.Prevalence of Pets in home 
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mong 149 patients 11 (7.4%) had pets in their home which 
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FACTORS
CONTROL 
 
A pet in home had influence mainly on control of asthma more than 
dose requirement and duration. In our study among 11 patients with exposure 
to pets at home, 3(27.3%) patients were under good 
patients with poor control [8(72.7%)] with family history. But this was not 
statistically significant.
.Table 34: Influence of 
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DISCUSSION 
 
This cross sectional study was undertaken to evaluate the effect of G-
protein receptor kinase-5 (GRK5) polymorphism on the usage of 
glucocorticoids in the treatment of bronchial asthma. The dose and duration of 
steroid use and the degree of control of the disease were correlated with the 
presence of GRK5 polymorphism. 
Asthma is a disease whose prevalence keeps increasing every year and 
steroid dependence in asthma is also on the rise. Even after proper institution of 
appropriate therapy, increasing numbers of people continue to have poor 
control of asthma151. 
Our central hypothesis was that an increased dose of steroid and a longer 
duration of treatment would be required for patients of bronchial asthma with a 
polymorphism, because this single nucleotide polymorphism (SNP) has been 
reported to cause endogenous beta adrenergic receptor blockade which might 
result in poorer overall disease control152.  
The primary inclusion criterion for our study was an asthmatic on 
maintenance therapy with inhaled corticosteroids. Patients were categorized as 
receiving low, medium or high dose of inhalational corticosteroid based on the 
GINA (Global Initiative for Asthma) guidelines for 2015149. Based on various 
studies done in the community150, patients receiving inhaled steroids for more 
than 3 months were considered as patients on long term steroid therapy and 
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those receiving inhaled steroids for less than 3 months were considered as 
patients on short term steroid therapy. 
  
 The total number of patients recruited in our study was 149, among 
which there were 53 males(35.5%) and 96 females(64.5%). Previous 
population based studies have shown female sex to be a risk factor for 
developing asthma153. This was also observed in our study where the male: 
female ratio was 1: 1.8. 
In our study we found that there was no significant influence of age over 
the prevalence of asthma (P=0.954). The number of patients in our study with 
age more than 40 years (51%) was almost equal to the number of patients with 
age less than 40 years (49%) and were most commonly in the age group of 41-
50 years [39 patients (26%)]. However another multicentric study done in India 
by Jindal et al154 showed an increased prevalence of asthma among the age 
group 15-54 years. 
We also studied other factors which are known to influence the mortality 
and morbidity of asthma, one amongst which is obesity. In our study, 50 
patients (33.5%) were overweight with a body mass index (BMI) ≥ 25 kg/m2, 
amongst which, 20 patients were obese with a BMI > 30kg/m2. Our results 
were similar to various community based studies which showed the prevalence 
of BMI ≥ 25 kg/m2as 30-50% among asthmatics155. 
Exposure to allergens at the work place is another factor which 
influences the outcome of asthma. In our study 12 patients (8%) had a history 
of exposure to allergens by working in tobacco industries, cotton mills, etc. 
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History of known allergy to cold weather, dust and pets is another 
important risk factor for asthma. In our study more than 79 patients (53%) had 
a history of allergy to the above mentioned factors. This is similar to various 
multicentric studies156 that showed a prevalence of known history of allergy or 
atopy in 49-63% of patients. 
Family history of asthma is another important risk factor which 
influences the severity of asthma. Our study had 16 patients (10.7%) with a 
family history of asthma and these results are similar to a study done in the 
United States in which the prevalence of positive family history in asthmatics 
ranged from 7-15%157 
In our study 21 patients (14%) had respiratory co-morbidities like 
respiratory tract infections, bronchiectasis, pneumonia or previous history of 
TB, which also influence the morbidity and severity of asthma. Allergic rhinitis 
is the most common respiratory co-morbidity associated with asthma with a 
prevalence of 20-40%158 among asthmatics. The prevalence of allergic rhinitis 
in our study was similar to previous studies, as 55 patients (37%) were also on 
treatment for allergic rhinitis. 
Obstructive sleep apnea (OSA), diagnosed by a sleep study, and was 
present in 13 patients (9%). This is almost similar to the prevalence of OSA in 
asthmatics as reported in literature - 10%– 20%159. 
 Gastro esophageal reflux disease (GERD) is another important risk 
factor for asthma with a known prevalence of more than 20%160. In our study 
the prevalence was slightly less when compared to the literature - 16 patients 
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(11%) had GERD. This could be due to differences in sample size and patient 
selection in our study compared to previous studies.  
Our primary aim was to evaluate the effect of GRK5 polymorphism in 
asthmatics on steroid therapy. We studied this gene because of its role in 
bronchial smooth muscle relaxation. The GRK5 gene controls the expression of 
a kinase which regulates the G-protein coupled receptors. Phosphorylation 
induced by GRK5 causes desensitization of the beta adrenergic receptor and 
enhances endogenous beta receptor blockade. Thus the activity of this kinase 
may influence disease control and hence the dose requirement and duration of 
steroid therapy in asthmatics. Agonist promoted β2-adrenergic receptor 
phosphorylation is greater in cells expressing GRK5-Leu41polymorphism, 
when compared to patients expressing a normal genotype. So GRK5-Leu 41 
polymorphism represents a detrimental gain-of-function mutation that causes 
an enhanced endogenous beta blockade, affecting bronchial smooth muscle 
relaxation and resulting in poor control of asthma. 
In our study, 17 of 149 patients (11.5%) had GRK5 polymorphism. 
Among those 17 patients, 14 patients were heterozygous, 3 were homozygous 
and the rest were wild type. It has been found that the prevalence of this 
polymorphism is variable between different ethnic populations. The GRK5-Leu 
41 variant is approximately 10-fold more common in African- Americans152. In 
some races the prevalence of the SNP is in around 2% of the population while 
in the African Americans it is as high as 36.2%152. Our study population had 
11.5% of GRK5-Leu41 variant. 
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Our objective was to study the effect of this SNP on the dosage and 
duration of treatment with inhaled corticosteroids and also the influence of the 
SNP on disease control.  
Hence we analyzed patients who required high dose inhaled steroids, 
classified based on the dosage guidelines in the GINA report of 2015 for 
different inhalational corticosteroids. The majority of patients in our study were 
receiving Budesonide or Fluticasone. In our study, 34 patients (23%) required 
high dose inhaled corticosteroids, amongst which 14 patients had SNP and 20 
patients had a normal genotype without polymorphism. Among 115 patients 
(77%) who required low dose inhaled corticosteroids, only 3 patients had the 
polymorphism. 
Interestingly the effect of SNP on requirement of high dose was 
statistically significant (P=0.000) with an odds ratio of 26.133 with confidence 
interval of 6.88 to 99.27. Based on this odds ratio, we can state that patients 
with GRK5 polymorphism have a very high probability of requiring high dose 
inhaled corticosteroids for adequate control of asthma. 
We also assessed the influence of various other factors which may have 
an effect on the dose requirement of steroids in asthmatics like age, sex, 
severity of disease, BMI, history of allergy or atopy, respiratory co morbidities 
like previous history of TB, respiratory infections etc, allergic rhinitis and 
GERD161.These factors were included as co-variates and analyzed individually 
using chi square test.  
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Among 34 patients requiring high dose inhaled steroids, 8 patients 
(23.5%) were overweight with BMI more than 25. Only 3 patients (8.8%) had 
respiratory co-morbidities. History of allergy or atopy was seen in 14 patients 
(41.1%). In our study, amongst the 34 patients requiring high dose inhaled 
steroids, 21 patients (61.7%) had poorly controlled disease. 14 patients (41.1%) 
had allergic rhinitis and 4 patients (11.8%) had GERD.  
Except for history of allergy or atopy, the ‘P’ value of all other factors 
was not statistically significant. In spite of P value of 0.004 for history of 
allergy or atopy, the odds ratio was less than 1 (OR=0.319) which indicated 
that there was no significant positive association between patients with history 
of allergy and requirement of high dose inhaled steroids.  
We also did a multinomial logistic regression analysis with the 
dependent factor as dose requirement, the factor influencing it as single 
nucleotide polymorphism and including all other factors considered as co-
variates. According to the analysis there was a statistically significant higher 
dose requirement in patients with SNP. 
Another objective was to explore the effect of polymorphism on longer 
duration of treatment with steroids. In our study group, the duration of steroid 
use ranged from one month to 5 years. Patients were classified based on 
duration of treatment as long term steroid use (≥ 3 months) and short term 
steroid use (≤ 3 months) based on various community-based studies150. In our 
study, higher proportion of patients were on long term treatment – 90 patients 
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(60%) were on long term steroids while 59 patients (40%) were on short term 
steroids. 
Amongst these 90 patients on long term steroids, 12 patients had SNP. 7 
patients in the short term steroids group had SNP. Curiously the effect of SNP 
on duration of steroid use was not statistically significant with ‘p’ value of 
0.362 and odds ratio of 1.662. 
We also analyzed the effect of all previous co-variates on the 
requirement of steroids for long term therapy161. All these factors were also not 
statistically significant in influencing the duration of treatment. We also did a 
multinomial logistic regression analysis with the dependent factor as duration 
of treatment, factor influencing it as single nucleotide polymorphism and 
including all other factors as co-variates. This did not show any statistically 
significant association even though the average duration of drug therapy is 
higher in SNP group(9.65 months) compared to non SNP group(9 months). 
Based on this analysis we can state that there is no significant effect of SNP on 
duration of treatment in our study, which implies that the effect of the SNP on 
the management of asthma is not dependent on the duration of steroid therapy. 
Finally we analyzed the effect of SNP on control of asthma, which was 
measured using the Asthma Control questionnaire, grouping patients having 
ACT score more than 20 as good control and less than 20 as poor control162. 
In our study group of 149 patients, 91 patients (61%) had poorly 
controlled asthma and 58 patients (39%) had good disease control. Amongst 
the 17 patients with SNP, 13 patients (76.5%) had good disease control and the 
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remaining 4 patients (23.5%) had poorly controlled asthma. This association 
was also statistically significant with ‘p’ value of 0.004 and odds ratio of 6.283. 
This is contrary to the expectation that the endogenous beta adrenergic receptor 
blockade promoted by this SNP would result in poor disease control.  
We also analyzed all the other co-variates which also influence the 
control of asthma and they were not found to be statistically significant, except 
for the presence of respiratory co-morbidities. Out of our study group of 149 
patients, 21 patients had a history of respiratory co-morbidities, amongst which 
17 patients had poorly controlled disease. This association is already well-
documented163. The association in our study was statistically significant with a 
P value of 0.044 and an odds ratio of 3.1.  
Hence we applied a multivariate logistic regression analysis with 
dependent factor as control of disease, factor influencing it as single nucleotide 
polymorphism and including all other factors as co-variates. This analysis 
showed a statistically significant association for asthmatics with GRK5 
polymorphism on inhaled steroids having good disease control. This could be 
explained from the fact that the SNP has a statistically significant association 
with high dose requirement of inhaled steroid, which leads to good control of 
the disease.  
Higher dose of glucocorticoids negating the expected effect of the GRK5 
polymorphism was also shown in a study done on rats by Judith et al in 
London145where they hypothesized that the impaired relaxation to β2-agonists 
after bronchoconstriction induced by IL-1β, may be due to an increase in the 
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expression and activity of GRKs, and that this could be reversed by 
glucocorticoids. The study results were significant in that dexamethasone 
caused complete inhibition of the increased GRK activity as well as the 
increased GRK2 and GRK5 protein expression induced by IL-1β. 
Similarly in our study, increased expression of GRK5 activity due to 
polymorphism, resulting in endogenous beta blockade and causing impaired 
relaxation, may have been reversed by intake of high dose inhaled steroids.  
To conclude, based on the analysis from our study, patients with GRK5 
polymorphism, receiving inhaled steroids for maintenance therapy of asthma, 
have more probability of requiring higher dose of inhaled steroid for adequate 
control of disease. Also administration of high dose steroid can reduce poor 
disease control due to the effect of the polymorphism. Disease control in 
patients with polymorphism is not dependent on the duration of inhaled steroid 
therapy. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Conclusion 
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CONCLUSION 
 
1. Asthmatics with GRK5 polymorphism have more probability of 
requiring high dose steroids for adequate control of disease 
2. GRK5 polymorphism does not have a significant effect on the 
duration of drug therapy. 
3. Though patients with polymorphism are expected to have poor control 
of their asthma, intake of high dose steroids may reverse the effect of the 
polymorphism and these patients may actually have adequate control of their 
disease. 
4. This study is the first of its type done in India - analyzing the effect of 
GRK5 polymorphism on steroid therapy in asthmatics. 
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Annexures 
Genomic DNA gel electrophoresis 
 
Image.1: Genomic DNA Agarose gel electrophoresis 
 
Image shows 0.8% agarose gel electrophoresis of the genomic DNA. 
Lanes shows the extracted DNA under UV trans illumination on 
ethidium bromide staining 
 
 
 
 
 
 
  
 
 
 
Image.2: 15% Polyacrylamide gel electrophoresis of restrict 
digestion product 
 
 
 
Lane1 shows the DNA ladder.Lanes 6,10 shows a heterozygous 
Rest shows wild type homozygous product. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Image.3: Genomic DNA Agarose gel electrophoresis
 
Image shows 0.8% agarose gel electrophoresis of the genomic 
DNA.Lanes shows the extracted DNA under UV transillumination on 
Lane 1 shows ladder 2,4 shows heterozygous . Lane 3,5 shows mutant 
ethidium bromide staining 
homozygous 
 
 
 
 
 
 
 
 
 
A study on the effect of GRK5 Gln41Leu polymorphism on 
response to glucocorticoid therapy in bronchial asthma 
Dr.E.AmudhanArvind, Dr.S.Ramalingam 
Case Report Form 
Patient name:     IP/OP no: 
Age/Gender:      Address: 
Contact number: 
Height:    Weight:                          
BMI; 
Occupation– (Current &Past): 
Any Hazardous exposure in work place: 
Ethnicity (Religion/caste) 
H/o known allergens: 
Personal History: 
Smoking – (cigar/beedi, how many, how long) 
Alcohol- 
Other Substance abuse- 
Family History 
(H/O, asthma, atopic dermatitis, Eczema, allergic rhinitis) 
Disease related details 
Asthma-> Duration of disease 
  Drug 
  Dose 
  Duration 
Started taking from: 
Route:  
Change in drug in recent past: 
Reason for change of drug: 
2) Co morbid conditions & treatment: 
 Respiratory system related: 
 Non Respiratory system related: 
  HT- 
  DM- 
  TB- 
  Others- 
  H/O Obstructive Sleep Apnea 
3) No of emergency visits in last year- 
4) No of hospitalization in last year- 
5) Treatment given: 
5) During past 4 weeks have you had any 
-respiratory infection 
-GERD symptoms 
-Rhino sinusitis 
Pet/farm animals in house: 
Other relevant history: 
Genotypic status of the patient: 
 
 
 
 
  
 
  
  
 
 
 
 
  
 
  
 
 
ABBREVATIONS 
 
WHO - World Health Organization 
COPD - chronic obstructive pulmonary disease 
SNP - Single Nucleotide Polymorphism 
GRK - G protein-coupled receptor kinase 
GPCR - G protein-coupled receptors 
BTS - British Thoracic Society 
NHLBI - NIH Heart, Lung and Blood Institute 
GINA - Global Initiative for Asthma 
IgE - Immunoglubulin E 
PG - prostaglandin 
LOX - Lipoxygenase 
ASM - Airway smooth muscle 
TH 1 & 2 – T-Helper cells 1&2 
AHR – Airway Hyperresponsiveness 
NF-KB - nuclear factor – kappa beta 
GATA-3 - Trans-acting T-cell-specific transcription factor 
PEFR - Peak Expiratory Flow Rate 
BA - Bronchial Asthma 
GERD – Gastro Esophageal Reflux Disease 
OSA – Obstructive Sleep Apnoea 
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